Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review

Idir Ouzaid, Umberto Capitanio, Michael Staehler, Christopher G. Wood, Bradley Leibovich, Börje Ljungberg, Hendrik Van Poppel, Karim Bensalah

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Context: The benefit of surgical metastasectomy (SM) for patients with metastatic renal cell carcinoma (mRCC) remains controversial because of the lack of high-level evidence on the role of SM in terms of survival benefit in the era of systemic therapy. Objective: To perform a systematic review of the literature on the role of SM in the treatment of mRCC and discuss key issues in the SM decision-making process. Evidence acquisition: A systematic search of the Embase and Medline databases was carried out and a systematic review of the role of SM in mRCC was performed. A total of 56 studies were finally included in the evidence synthesis. Evidence synthesis: All the studies included were retrospective and mostly noncomparative. Median overall survival (OS) ranged from 36 to 142 mo for those undergoing SM, compared to 8–27 mo for no SM. SM was associated with a lower risk of all-cause mortality compared to no SM (pooled adjusted hazard ratio 2.37, 95% confidence interval 2.03–2.87; p < 0.001). Morbidity and mortality were similar for SM and primary tumor surgery. The most important prognostic factor for OS was complete resection of metastases. Other prognostic factors included disease free-survival from nephrectomy, primary tumor features (T stage ≥3, high grade, sarcomatoid features, and pathological nodal status), the number of metastases, and performance status. Lung metastasectomy seemed to show the best survival benefit. Conclusions: Although no randomized clinical data are available, published studies support the role of SM in selected patients in the modern era. Complete SM allows sustained survival free of systemic treatment. Integration of SM and systemic therapy in a multimodal approach remains a valid option for some patients. Patient summary: Surgical resection of metastases originating from renal cell carcinoma may play a role in prolonging survival and avoiding systemic therapy when complete resection is achievable. This strategy is an option for selected patients with a limited number of metastases who still have good general health status. Surgical metastasectomy in renal cell carcinoma has potential benefits. It offers prolonged survival in a subgroup of patients with slowly growing disease and allows survival free from medical treatment, thus avoiding treatment-related toxicities. Complete resection is the primary goal in all patients. However, relief of metastases-related symptoms is also an indication for the procedure. Features identifying the best candidates for metastasectomy include achievable complete resection, good performance status, a long disease-free interval (from nephrectomy), and limited metastatic sites, ideally in the lungs. In all cases, the decision should be individualized and closely discussed within dedicated multidisciplinary cancer centers.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalEuropean Urology Oncology
Volume2
Issue number2
DOIs
StatePublished - Mar 1 2019

Fingerprint

Metastasectomy
Renal Cell Carcinoma
Survival
Neoplasm Metastasis
Nephrectomy
Therapeutics
Disease-Free Survival
Neoplasms
Lung

Keywords

  • Metastasectomy
  • Metastases
  • Renal cell carcinoma
  • Surgery
  • Treatment

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Surgery
  • Oncology
  • Urology

Cite this

Ouzaid, I., Capitanio, U., Staehler, M., Wood, C. G., Leibovich, B., Ljungberg, B., ... Bensalah, K. (2019). Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. European Urology Oncology, 2(2), 141-149. https://doi.org/10.1016/j.euo.2018.08.028

Surgical Metastasectomy in Renal Cell Carcinoma : A Systematic Review. / Ouzaid, Idir; Capitanio, Umberto; Staehler, Michael; Wood, Christopher G.; Leibovich, Bradley; Ljungberg, Börje; Van Poppel, Hendrik; Bensalah, Karim.

In: European Urology Oncology, Vol. 2, No. 2, 01.03.2019, p. 141-149.

Research output: Contribution to journalReview article

Ouzaid, I, Capitanio, U, Staehler, M, Wood, CG, Leibovich, B, Ljungberg, B, Van Poppel, H & Bensalah, K 2019, 'Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review', European Urology Oncology, vol. 2, no. 2, pp. 141-149. https://doi.org/10.1016/j.euo.2018.08.028
Ouzaid I, Capitanio U, Staehler M, Wood CG, Leibovich B, Ljungberg B et al. Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. European Urology Oncology. 2019 Mar 1;2(2):141-149. https://doi.org/10.1016/j.euo.2018.08.028
Ouzaid, Idir ; Capitanio, Umberto ; Staehler, Michael ; Wood, Christopher G. ; Leibovich, Bradley ; Ljungberg, Börje ; Van Poppel, Hendrik ; Bensalah, Karim. / Surgical Metastasectomy in Renal Cell Carcinoma : A Systematic Review. In: European Urology Oncology. 2019 ; Vol. 2, No. 2. pp. 141-149.
@article{741e4717014140e9b612225889b9597c,
title = "Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review",
abstract = "Context: The benefit of surgical metastasectomy (SM) for patients with metastatic renal cell carcinoma (mRCC) remains controversial because of the lack of high-level evidence on the role of SM in terms of survival benefit in the era of systemic therapy. Objective: To perform a systematic review of the literature on the role of SM in the treatment of mRCC and discuss key issues in the SM decision-making process. Evidence acquisition: A systematic search of the Embase and Medline databases was carried out and a systematic review of the role of SM in mRCC was performed. A total of 56 studies were finally included in the evidence synthesis. Evidence synthesis: All the studies included were retrospective and mostly noncomparative. Median overall survival (OS) ranged from 36 to 142 mo for those undergoing SM, compared to 8–27 mo for no SM. SM was associated with a lower risk of all-cause mortality compared to no SM (pooled adjusted hazard ratio 2.37, 95{\%} confidence interval 2.03–2.87; p < 0.001). Morbidity and mortality were similar for SM and primary tumor surgery. The most important prognostic factor for OS was complete resection of metastases. Other prognostic factors included disease free-survival from nephrectomy, primary tumor features (T stage ≥3, high grade, sarcomatoid features, and pathological nodal status), the number of metastases, and performance status. Lung metastasectomy seemed to show the best survival benefit. Conclusions: Although no randomized clinical data are available, published studies support the role of SM in selected patients in the modern era. Complete SM allows sustained survival free of systemic treatment. Integration of SM and systemic therapy in a multimodal approach remains a valid option for some patients. Patient summary: Surgical resection of metastases originating from renal cell carcinoma may play a role in prolonging survival and avoiding systemic therapy when complete resection is achievable. This strategy is an option for selected patients with a limited number of metastases who still have good general health status. Surgical metastasectomy in renal cell carcinoma has potential benefits. It offers prolonged survival in a subgroup of patients with slowly growing disease and allows survival free from medical treatment, thus avoiding treatment-related toxicities. Complete resection is the primary goal in all patients. However, relief of metastases-related symptoms is also an indication for the procedure. Features identifying the best candidates for metastasectomy include achievable complete resection, good performance status, a long disease-free interval (from nephrectomy), and limited metastatic sites, ideally in the lungs. In all cases, the decision should be individualized and closely discussed within dedicated multidisciplinary cancer centers.",
keywords = "Metastasectomy, Metastases, Renal cell carcinoma, Surgery, Treatment",
author = "Idir Ouzaid and Umberto Capitanio and Michael Staehler and Wood, {Christopher G.} and Bradley Leibovich and B{\"o}rje Ljungberg and {Van Poppel}, Hendrik and Karim Bensalah",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.euo.2018.08.028",
language = "English (US)",
volume = "2",
pages = "141--149",
journal = "European urology oncology",
issn = "2588-9311",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Surgical Metastasectomy in Renal Cell Carcinoma

T2 - A Systematic Review

AU - Ouzaid, Idir

AU - Capitanio, Umberto

AU - Staehler, Michael

AU - Wood, Christopher G.

AU - Leibovich, Bradley

AU - Ljungberg, Börje

AU - Van Poppel, Hendrik

AU - Bensalah, Karim

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Context: The benefit of surgical metastasectomy (SM) for patients with metastatic renal cell carcinoma (mRCC) remains controversial because of the lack of high-level evidence on the role of SM in terms of survival benefit in the era of systemic therapy. Objective: To perform a systematic review of the literature on the role of SM in the treatment of mRCC and discuss key issues in the SM decision-making process. Evidence acquisition: A systematic search of the Embase and Medline databases was carried out and a systematic review of the role of SM in mRCC was performed. A total of 56 studies were finally included in the evidence synthesis. Evidence synthesis: All the studies included were retrospective and mostly noncomparative. Median overall survival (OS) ranged from 36 to 142 mo for those undergoing SM, compared to 8–27 mo for no SM. SM was associated with a lower risk of all-cause mortality compared to no SM (pooled adjusted hazard ratio 2.37, 95% confidence interval 2.03–2.87; p < 0.001). Morbidity and mortality were similar for SM and primary tumor surgery. The most important prognostic factor for OS was complete resection of metastases. Other prognostic factors included disease free-survival from nephrectomy, primary tumor features (T stage ≥3, high grade, sarcomatoid features, and pathological nodal status), the number of metastases, and performance status. Lung metastasectomy seemed to show the best survival benefit. Conclusions: Although no randomized clinical data are available, published studies support the role of SM in selected patients in the modern era. Complete SM allows sustained survival free of systemic treatment. Integration of SM and systemic therapy in a multimodal approach remains a valid option for some patients. Patient summary: Surgical resection of metastases originating from renal cell carcinoma may play a role in prolonging survival and avoiding systemic therapy when complete resection is achievable. This strategy is an option for selected patients with a limited number of metastases who still have good general health status. Surgical metastasectomy in renal cell carcinoma has potential benefits. It offers prolonged survival in a subgroup of patients with slowly growing disease and allows survival free from medical treatment, thus avoiding treatment-related toxicities. Complete resection is the primary goal in all patients. However, relief of metastases-related symptoms is also an indication for the procedure. Features identifying the best candidates for metastasectomy include achievable complete resection, good performance status, a long disease-free interval (from nephrectomy), and limited metastatic sites, ideally in the lungs. In all cases, the decision should be individualized and closely discussed within dedicated multidisciplinary cancer centers.

AB - Context: The benefit of surgical metastasectomy (SM) for patients with metastatic renal cell carcinoma (mRCC) remains controversial because of the lack of high-level evidence on the role of SM in terms of survival benefit in the era of systemic therapy. Objective: To perform a systematic review of the literature on the role of SM in the treatment of mRCC and discuss key issues in the SM decision-making process. Evidence acquisition: A systematic search of the Embase and Medline databases was carried out and a systematic review of the role of SM in mRCC was performed. A total of 56 studies were finally included in the evidence synthesis. Evidence synthesis: All the studies included were retrospective and mostly noncomparative. Median overall survival (OS) ranged from 36 to 142 mo for those undergoing SM, compared to 8–27 mo for no SM. SM was associated with a lower risk of all-cause mortality compared to no SM (pooled adjusted hazard ratio 2.37, 95% confidence interval 2.03–2.87; p < 0.001). Morbidity and mortality were similar for SM and primary tumor surgery. The most important prognostic factor for OS was complete resection of metastases. Other prognostic factors included disease free-survival from nephrectomy, primary tumor features (T stage ≥3, high grade, sarcomatoid features, and pathological nodal status), the number of metastases, and performance status. Lung metastasectomy seemed to show the best survival benefit. Conclusions: Although no randomized clinical data are available, published studies support the role of SM in selected patients in the modern era. Complete SM allows sustained survival free of systemic treatment. Integration of SM and systemic therapy in a multimodal approach remains a valid option for some patients. Patient summary: Surgical resection of metastases originating from renal cell carcinoma may play a role in prolonging survival and avoiding systemic therapy when complete resection is achievable. This strategy is an option for selected patients with a limited number of metastases who still have good general health status. Surgical metastasectomy in renal cell carcinoma has potential benefits. It offers prolonged survival in a subgroup of patients with slowly growing disease and allows survival free from medical treatment, thus avoiding treatment-related toxicities. Complete resection is the primary goal in all patients. However, relief of metastases-related symptoms is also an indication for the procedure. Features identifying the best candidates for metastasectomy include achievable complete resection, good performance status, a long disease-free interval (from nephrectomy), and limited metastatic sites, ideally in the lungs. In all cases, the decision should be individualized and closely discussed within dedicated multidisciplinary cancer centers.

KW - Metastasectomy

KW - Metastases

KW - Renal cell carcinoma

KW - Surgery

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85061027365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061027365&partnerID=8YFLogxK

U2 - 10.1016/j.euo.2018.08.028

DO - 10.1016/j.euo.2018.08.028

M3 - Review article

C2 - 31017089

AN - SCOPUS:85061027365

VL - 2

SP - 141

EP - 149

JO - European urology oncology

JF - European urology oncology

SN - 2588-9311

IS - 2

ER -